Do Analysts Agree Wednesday on Mirati Therapeutics Inc (MRTX) Stock's Target Price?
Wednesday, September 15, 2021 03:23 PM | InvestorsObserver Analysts
Mentioned in this article
Wall Street is positive on Mirati Therapeutics Inc (MRTX). On average, analysts give MRTX a Buy rating. The average price target is $191, which means analysts expect the stock to rise by 12.87% over the next twelve months.
That average ranking earns MRTX an Analyst Rating of 29, which is better than 29% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating MRTX a Buy today. Find out what this means to you and get the rest of the rankings on MRTX!
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Mirati Therapeutics Inc Stock Today?
Mirati Therapeutics Inc (MRTX) stock is trading at $169.22 as of 3:23 PM on Wednesday, Sep 15, a rise of $9.02, or 5.63% from the previous closing price of $160.20. The stock has traded between $160.53 and $169.36 so far today. Volume today is 291,542 compared to average volume of 340,937.
Click Here to get the full Stock Report for Mirati Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter